{{Chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 442867817 | ImageFile = Morphiceptin.svg | ImageClass = skin-invert-image | ImageSize = | ImageAlt = | IUPACName = (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide<ref name=ChemBase>{{cite web|title=Morphiceptin|url=http://www.chembase.com/cbid_119303.htm|publisher=ChemBase|access-date=1 August 2011|archive-url=https://web.archive.org/web/20120315180103/http://www.chembase.com/cbid_119303.htm|archive-date=15 March 2012|url-status=dead}}</ref> | OtherNames = Tyr-Pro-Phe-Pro-NH2, PLO17 |Section1={{Chembox Identifiers | CASNo_Ref = {{cascite|correct|CAS}} | CASNo = 74135-04-9 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 97TZA8ANPC | PubChem = 119303 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 106565 | SMILES = c1ccc(cc1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](Cc4ccc(cc4)O)N | InChI = 1/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21-,22-,23-,24-/m0/s1 | InChIKey = LSQXZIUREIDSHZ-ZJZGAYNABZ | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21-,22-,23-,24-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = LSQXZIUREIDSHZ-ZJZGAYNASA-N }} |Section2={{Chembox Properties | Formula = C<sub>28</sub>H<sub>35</sub>N<sub>5</sub>O<sub>5</sub> | MolarMass = 521.6 g/mol | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = }} |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }} }}
'''Morphiceptin''' is a tetrapeptide (Tyr-Pro-Phe-Pro-NH<sub>2</sub>) that is a selective μ-opioid receptor agonist. It is derived from β-casomorphin and has over 1,000 times selectivity for μ- over δ-opioid receptors. When injected intracerebroventricularly (into the ventricular system of the brain), morphiceptin had an analgesic ED<sub>50</sub> of 1.7 nmol per animal. The analgesic effects of morphiceptin were reversed by naloxone, meaning that the analgesic effect is mediated by the μ-opioid receptor.<ref name="Chang 1982">{{cite journal|last=Chang|first=K|title=Analgesic activity of intracerebroventricular administration of morphiceptin and β-casomorphins: Correlation with the morphine (μ) receptor binding affinity|journal=Life Sciences|date=3 May 1982|volume=30|issue=18|pages=1547–1551|doi=10.1016/0024-3205(82)90242-9|pmid=6281604}}</ref>
Morphiceptin is the (1S,2S,3S,4S)-form whereas deproceptin is the (1S,2S,3S,4R)-form [84799-23-5].
== See also == * Casokefamide
== References == {{Reflist}}
{{Opioidergics}}
Category:Analgesics Category:Opioid peptides Category:Tetrapeptides